Kindred biosciences, inc. (KIN)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12
Net product revenues

603

1,401

1,104

1,236

515

-

640

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue from Contract with Customer, Including Assessed Tax

-

-

-

-

-

1,326

-

-

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating costs and expenses:
Cost of product revenues

3,577

187

139

169

92

214

110

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

8,867

7,134

7,290

6,734

7,152

7,756

7,477

5,820

5,346

5,142

4,877

3,866

3,780

3,509

3,754

3,161

3,437

4,579

5,033

4,991

4,809

4,802

3,755

5,639

4,498

1,746

953

300

141

75

Selling, general and administrative

-

-

9,382

9,065

-

-

6,608

5,770

4,902

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative

8,873

9,578

-

-

9,901

9,219

-

-

-

4,820

3,269

3,056

2,843

2,401

2,022

1,865

2,020

1,881

2,095

1,921

1,953

2,014

2,342

2,504

1,679

641

259

96

83

45

Restructuring costs

1,676

-

-

-

0

-

-

-

-

-

-

-

-

0

0

0

655

0

0

0

0

-

-

-

-

-

-

-

-

-

Total operating costs and expenses

22,993

-

-

-

17,145

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating costs and expenses

-

-

16,811

15,968

-

17,189

14,195

11,590

10,248

9,962

8,146

6,922

6,623

5,910

5,776

5,026

6,112

6,460

7,128

6,912

6,762

6,816

6,097

8,143

6,177

2,387

1,212

396

224

120

Loss from operations

-22,390

-15,498

-15,707

-14,732

-16,630

-15,863

-13,555

-11,590

-10,248

-9,962

-8,146

-6,922

-6,623

-5,910

-5,776

-5,026

-6,112

-6,460

-7,128

-6,912

-6,762

-6,816

-6,097

-8,143

-6,177

-2,387

-1,212

-396

-224

-120

Interest and other (expense) income, net

-371

-

-

-

575

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest and other income, net

-

-236

414

425

-

422

518

349

277

232

256

155

131

101

93

79

52

40

33

29

30

-

-

-

-

-

-

-

-

-

Interest and other income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

27

25

33

9

4

2

0

0

0

Net loss

-22,761

-15,734

-15,293

-14,307

-16,055

-15,441

-13,037

-11,241

-9,971

-9,730

-7,890

-6,767

-6,492

-5,809

-5,683

-4,947

-6,060

-6,420

-7,095

-6,883

-6,732

-6,789

-6,072

-8,110

-6,168

-2,383

-1,210

-396

-224

-120

Change in unrealized gains or losses on available-for-sale securities

9

5

-5

-26

2

-2

-12

-17

11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in unrealized gains or losses on available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Comprehensive loss

-22,770

-15,739

-15,288

-14,281

-16,057

-15,439

-13,025

-11,224

-9,982

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-120

Net loss per share, basic and diluted (in usd per share)

-0.58

-0.40

-0.39

-0.37

-0.42

-0.46

-0.39

-0.39

-0.36

-0.35

-0.29

-0.29

-0.30

-0.29

-0.29

-0.25

-0.31

-0.32

-0.36

-0.35

-0.34

-0.34

-0.31

-0.42

-0.38

-0.40

-0.40

-0.13

-0.07

-0.06

Weighted-average number of common shares outstanding, basic and diluted (in shares)

39,186

38,999

38,940

38,887

37,786

33,708

33,601

28,619

27,986

27,915

27,400

23,409

21,516

19,900

19,891

19,865

19,836

19,816

19,792

19,756

19,726

19,719

19,713

19,426

16,222

5,899

3,005

3,000

3,000

2,113